novartis ceo: we expect our six key drugs to grow ahead of analyst expectations
Published 1 year ago • 11K plays • Length 4:17Download video MP4
Download video MP3
Similar videos
-
5:53
novartis expects 'strong momentum' going into second half, says ceo vasant narasimhan
-
6:12
novartis ceo: expect continued growth in 2023
-
4:43
novartis ceo: our leukemia drug scemblix is a potential $3 billion plus medicine
-
3:47
novartis ceo: demand has surged for therapeutics
-
3:34
expect concrete decision before the end of the year on sandoz, says novartis ceo
-
43:50
vasant narasimhan, chief executive officer, novartis | bsr18
-
25:17
novartis ceo vas narasimhan: how to be a boss in an “unbossed” company
-
23:37
reimagining medicine with data & digital | novartis ceo at #vivatech19
-
1:58
novartis raises outlook after sandoz generics spinoff
-
8:47
novartis ceo: prescriptions in the pipeline | mad money | cnbc
-
3:33
novartis starts strategic review of sandoz generic drug unit: ceo
-
4:22
novartis ceo on new cancer therapy programs
-
3:29
novartis generated $40 billion in innovative medicine sales, says ceo
-
4:16
novartis ceo vas narasimhan: our medicines are starting to take market share and deliver on promises
-
7:51
watch cnbc's full interview with novartis ceo vas narasimhan
-
2:18
novartis ceo: we're moving toward filing covid drug from molecular partners with fda
-
0:45
novartis ceo: company set to become a pure play, innovative medicine business after sandoz spin off
-
2:47
novartis to release new gene therapy drug that could cost $2 million
-
0:41
how sandoz plans to grow after splitting from novartis
-
6:51
novartis ceo discusses how ai will impact drug development
-
3:43
novartis ceo vas narasimhan on the latest research on a breast cancer drug
-
2:05
ceo of swiss drugmaker novartis outlines some major industry trends for 2024